<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757859</url>
  </required_header>
  <id_info>
    <org_study_id>16D.083</org_study_id>
    <nct_id>NCT02757859</nct_id>
  </id_info>
  <brief_title>High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled WAter or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies how well high volume washing of the abdomen works in
      increasing survival after surgery in patients with pancreatic cancer that can be removed by
      surgery. High volume washings may remove free floating cancers present after surgery and help
      prolong survival in patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Overall survival (OS) (18 to 27 months after resection).

      SECONDARY OBJECTIVES:

      I. Disease free survival (DFS). II. Complication rate. III. Site of first-recurrence (by
      site, and distant vs. local). IV. Clearance of malignant cells pre vs. post-lavage.

      OUTLINE: Patients are randomized to 1 of 3 arms.

      Arm I (EIPL-S) extensive intraoperative peritoneal saline lavage: Patients undergo
      pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after
      removal of tumor, patients receive extensive intraoperative peritoneal saline (EIPL-S) lavage
      10 times over 15 minutes.

      Arm II (EIPL-D) extensive intraoperative peritoneal distilled water lavage: Patients undergo
      pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after
      removal of tumor, patients receive extensive intraoperative peritoneal distilled water
      (EIPL-D) lavage 10 times over 15 minutes.

      Arm III (NO LAVAGE): Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or
      total pancreatectomy with no extensive lavage after removal of tumor.

      After completion of study treatment, patients are followed up every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 27 months after resection</time_frame>
    <description>Will use a one-sided log-rank test to separately compare lavage (EIPL-S or EIPL=D) to no lavage with respect to OS. Assuming the study is not stopped at the interim analyses, the final comparison will be made with an alpha level of 0.02493. Distribution of OS will be estimated using the Kaplan-Meier method. Secondary analyses will use Cox regression to adjust the lavage/no lavage comparison for other baseline patient and/or characteristics known to be associated with OS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of overall complications and specific complications graded in severity using Common Terminology Criteria for Adverse Events (v4.0)</measure>
    <time_frame>Up to 5 years after resection</time_frame>
    <description>Will use chi-square or Fisher's exact test for dichotomous outcomes and Poisson regression for count outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free survival</measure>
    <time_frame>Up to 5 years after resection</time_frame>
    <description>Will use log-rank tests for time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival rate</measure>
    <time_frame>At 1 year after resection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site of first recurrence</measure>
    <time_frame>Up to 5 years after resection</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">667</enrollment>
  <condition>Acinar Cell Carcinoma</condition>
  <condition>Ampulla of Vater Adenocarcinoma</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Duodenal Adenocarcinoma</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type</condition>
  <condition>Periampullary Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (EIPL-S)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal saline EIPL-S lavage 10 times over 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (EIPL-D)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal distilled water EIPL-D lavage 10 times over 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM III (NO LAVAGE)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatectomy</intervention_name>
    <description>Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy</description>
    <arm_group_label>Arm I (EIPL-S)</arm_group_label>
    <arm_group_label>Arm II (EIPL-D)</arm_group_label>
    <arm_group_label>ARM III (NO LAVAGE)</arm_group_label>
    <other_name>Excision of the Pancreas</other_name>
    <other_name>Pancreas Excision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lavage</intervention_name>
    <description>Receive extensive intraoperative peritoneal saline (EIPL-S) lavage</description>
    <arm_group_label>Arm I (EIPL-S)</arm_group_label>
    <arm_group_label>Arm II (EIPL-D)</arm_group_label>
    <other_name>Irrigation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a surgical indication for pancreatectomy (pancreaticoduodenectomy,
             distal pancreatectomy, total pancreatectomy)

          -  A diagnosis of pancreatic or other periampullary cancer is suspected preoperatively

          -  In the opinion of the surgeon, the subject has no medical contraindications to
             pancreatectomy

          -  The subject is willing to consent to randomization of lavage vs. standard lavage

        Exclusion Criteria:

          -  The subject does not have a surgical indication for pancreatectomy

          -  In the opinion of the surgeon, the subject has medical contraindications to
             pancreatectomy

          -  The subject is not willing to consent to EIPL-S lavage vs. EIPL-D lavage vs. standard

          -  Subject with neoadjuvant chemotherapy or chemoradiation

          -  Known benign or indolent disease, including benign pancreatic cystic tumors or
             pancreatic endocrine tumors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Winter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordan Winter, MD</last_name>
    <phone>215-955-8874</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Winter, MD</last_name>
      <phone>215-955-8874</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Acinar Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

